[Other] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial |
|
This post will be closed automatically in 2026-11-13 02:56
Reward10points
|
10
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
30
Effects of Magnesium Supplementation on Muscle Soreness and Performance
20
Surgical Margins in Musculoskeletal Sarcoma
40
Influence of Allelopathic Factor on the Formation of Relationship between the Content of Proteins, Carbohydrates, and Lipids in the Cells of Green Microalgae
30
International journal of computerized dentistry, vol.0,
